CL2017002729A1 - Proteína de unión a rgma y su uso - Google Patents

Proteína de unión a rgma y su uso

Info

Publication number
CL2017002729A1
CL2017002729A1 CL2017002729A CL2017002729A CL2017002729A1 CL 2017002729 A1 CL2017002729 A1 CL 2017002729A1 CL 2017002729 A CL2017002729 A CL 2017002729A CL 2017002729 A CL2017002729 A CL 2017002729A CL 2017002729 A1 CL2017002729 A1 CL 2017002729A1
Authority
CL
Chile
Prior art keywords
rgma
union
seq
prevent
providing
Prior art date
Application number
CL2017002729A
Other languages
English (en)
Inventor
Motonori Hashimoto
Toshihide Yamashita
Original Assignee
Mitsubishi Tanabe Pharma Corp
Univ Osaka
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Univ Osaka, Univ Chiba Nat Univ Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CL2017002729A1 publication Critical patent/CL2017002729A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN TIENE POR OBJETO OBTENER UNA MOLÉCULA GUÍA ANTI-REPELENTE A (RGMA) QUE TENGA UNA ALTA ACTIVIDAD DE UNIÓN Y POCOS EFECTOS SECUNDARIOS QUE SE PUEDAN USAR COMO MEDICAMENTO PARA PREVENIR, TRATAR O PREVENIR LA RECAÍDA DE ENFERMEDADES NEUROLÓGICAS O INMUNOLÓGICAS. EL PROBLEMA SE RESUELVE PROPORCIONANDO UNA PROTEÍNA DE UNIÓN A RGMA AISLADA QUE NO INHIBE LA UNIÓN ENTRE RGMA Y NEOGENINA SINO QUE NEUTRALIZA LA ACTIVIDAD INHIBIDORA DE LA PROLIFERACIÓN DE NEURITAS DE RGMA, PREFERIBLEMENTE PROPORCIONANDO UN ANTICUERPO ANTI-RGMA QUE TIENE REGIONES DETERMINANTES DE COMPLEMENTARIEDAD QUE TIENEN SECUENCIAS DE AMINOÁCIDOS DE SEQ ID NOS: 30-35 O SEQ ID NO: 36-40 EN EL LISTADO DE SECUENCIAS, Y SFG.</p>
CL2017002729A 2015-04-28 2017-10-26 Proteína de unión a rgma y su uso CL2017002729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015091095 2015-04-28

Publications (1)

Publication Number Publication Date
CL2017002729A1 true CL2017002729A1 (es) 2018-06-08

Family

ID=57198582

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002729A CL2017002729A1 (es) 2015-04-28 2017-10-26 Proteína de unión a rgma y su uso

Country Status (34)

Country Link
US (3) US10287346B2 (es)
EP (2) EP3584260A1 (es)
JP (6) JP6497760B2 (es)
KR (4) KR20230173734A (es)
CN (2) CN113801225A (es)
AU (2) AU2016253886B2 (es)
BR (1) BR112017022994A2 (es)
CA (1) CA2983898A1 (es)
CL (1) CL2017002729A1 (es)
CO (1) CO2017011975A2 (es)
CR (2) CR20200517A (es)
CY (1) CY1122569T1 (es)
DK (1) DK3290441T3 (es)
DO (1) DOP2017000248A (es)
ES (1) ES2758480T3 (es)
GT (1) GT201700224A (es)
HK (1) HK1245808A1 (es)
HR (1) HRP20192099T1 (es)
HU (1) HUE047146T2 (es)
IL (2) IL287291B (es)
LT (1) LT3290441T (es)
MX (2) MX2017013894A (es)
PE (2) PE20180251A1 (es)
PH (1) PH12017501941A1 (es)
PL (1) PL3290441T3 (es)
PT (1) PT3290441T (es)
RS (1) RS59847B1 (es)
RU (1) RU2705304C2 (es)
SA (1) SA517390230B1 (es)
SG (1) SG11201708848TA (es)
SI (1) SI3290441T1 (es)
TW (3) TW202138389A (es)
WO (1) WO2016175236A1 (es)
ZA (2) ZA201708047B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016253886B2 (en) * 2015-04-28 2019-05-16 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
US11035534B2 (en) 2017-05-25 2021-06-15 Signify Holding B.V. Luminaire
MX2021000324A (es) 2018-07-10 2021-03-25 Mitsubishi Tanabe Pharma Corp Metodo de prevencion o tratamiento para neuropatia periferica o enfermedad acompa?ada por dolor en la que se reconoce la neuropatia periferica o trastorno de astrocitos.
US20210269535A1 (en) * 2018-07-19 2021-09-02 The University Of Tokyo Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
CN114945385A (zh) * 2020-01-15 2022-08-26 国立大学法人大阪大学 痴呆症的预防或治疗剂
US20230055626A1 (en) * 2020-01-15 2023-02-23 Osaka University Agent for prevention or treatment of diabetic autonomic neuropathy
CN112138146B (zh) * 2020-09-25 2022-08-09 安徽医科大学 Manf蛋白的应用
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
WO2024101345A1 (ja) * 2022-11-07 2024-05-16 国立大学法人大阪大学 異常タンパク質の凝集体蓄積が関与する疾患の予防又は治療剤

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
WO1999008533A1 (en) 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000032746A2 (en) 1998-11-30 2000-06-08 Millennium Pharmaceuticals, Inc. Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US20030103945A1 (en) 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003089608A2 (en) 2002-04-18 2003-10-30 The General Hospital Corporation Drg11-responsive (dragon) gene family
WO2004003150A2 (en) * 2002-06-26 2004-01-08 Yale University Modulators and modulation of the interacton between rgm and neogenin
US20040199186A1 (en) 2003-04-04 2004-10-07 Kuffler Suzanne Elizabeth Implant to promote axon regeneration across spinal cord and peripheral nerve gaps
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
AU2005221471A1 (en) 2004-03-11 2005-09-22 Bioclues, Inc Axon regeneration promoter
CN1950108A (zh) * 2004-03-11 2007-04-18 生物线索株式会社 轴突再生促进剂
WO2006019904A1 (en) 2004-07-14 2006-02-23 University Of Utha Research Foundation Netrin-related compositions and uses
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7449442B2 (en) 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
EP1928905B1 (de) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US20080051319A1 (en) 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
JPWO2008038599A1 (ja) * 2006-09-25 2010-01-28 国立大学法人 千葉大学 軸索再生促進剤
EP1906185A1 (en) 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101306193A (zh) 2008-05-15 2008-11-19 复旦大学 人神经突起生长素在制备创伤愈合药物中的应用
CA2724199C (en) 2008-06-06 2016-07-26 Children's Medical Center Corporation Promoting axon regeneration in the adult cns through control of protein translation
JP2010146801A (ja) 2008-12-17 2010-07-01 Kurita Water Ind Ltd 微生物発電方法及び微生物発電装置
DK2510001T3 (en) * 2009-12-08 2016-02-29 Abbvie Deutschland MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
EP2510948B1 (en) * 2009-12-09 2015-09-09 Mitsubishi Tanabe Pharma Corporation T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
JP6342812B2 (ja) * 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
UA118083C2 (uk) * 2012-01-27 2018-11-26 Еббві Дойчланд Гмбх Унд Ко. Кг ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО ПРОТИ МОЛЕКУЛИ ВІДШТОВХУВАЛЬНОГО НАПРЯМНОГО СИГНАЛУ (RGMa) ТА ЙОГО ЗАСТОСУВАННЯ В ЛІКУВАННІ РОЗЛАДУ, АСОЦІЙОВАНОГО З ДЕГЕНЕРАЦІЄЮ НЕЙРИТІВ
WO2013113107A1 (en) 2012-02-03 2013-08-08 University Health Network Methods for promoting neuron survival, axonal growth and/or regeneration
GB201203180D0 (en) * 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
PE20160690A1 (es) * 2013-03-18 2016-08-14 Biocerox Prod Bv Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
JP2016533318A (ja) 2013-09-17 2016-10-27 ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション Ｒｇｍａ／ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用
WO2015120138A2 (en) 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
AU2016253886B2 (en) * 2015-04-28 2019-05-16 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
CN105925578A (zh) 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA

Also Published As

Publication number Publication date
DK3290441T3 (da) 2020-01-02
IL255293B (en) 2021-10-31
IL287291A (en) 2021-12-01
EP3290441A1 (en) 2018-03-07
RU2705304C2 (ru) 2019-11-06
CA2983898A1 (en) 2016-11-03
KR102451786B1 (ko) 2022-10-05
IL287291B (en) 2022-09-01
JPWO2016175236A1 (ja) 2018-04-19
WO2016175236A1 (ja) 2016-11-03
EP3290441B1 (en) 2019-10-30
KR20230173734A (ko) 2023-12-27
CO2017011975A2 (es) 2018-02-20
CR20200517A (es) 2021-01-12
SA517390230B1 (ar) 2021-06-09
US20180100012A1 (en) 2018-04-12
KR20220140023A (ko) 2022-10-17
JP2023120374A (ja) 2023-08-29
JP7307446B2 (ja) 2023-07-12
TW201710296A (zh) 2017-03-16
IL255293A0 (en) 2017-12-31
JP2023030057A (ja) 2023-03-07
US11008388B2 (en) 2021-05-18
GT201700224A (es) 2019-07-26
HK1245808A1 (zh) 2018-08-31
KR102040235B1 (ko) 2019-11-05
CN107531791B (zh) 2021-09-07
JP2021106587A (ja) 2021-07-29
KR20190124350A (ko) 2019-11-04
CN113801225A (zh) 2021-12-17
AU2016253886B2 (en) 2019-05-16
BR112017022994A2 (pt) 2019-11-19
JP7306660B2 (ja) 2023-07-11
TWI732757B (zh) 2021-07-11
US20210277098A1 (en) 2021-09-09
PE20180251A1 (es) 2018-02-02
JP6955721B2 (ja) 2021-10-27
US20190270799A1 (en) 2019-09-05
CR20170539A (es) 2018-04-20
MX2022005565A (es) 2022-06-09
PE20230381A1 (es) 2023-03-06
RU2017135353A (ru) 2019-04-08
JP2019141048A (ja) 2019-08-29
RS59847B1 (sr) 2020-02-28
ES2758480T3 (es) 2020-05-05
SI3290441T1 (sl) 2020-03-31
RU2019134410A (ru) 2020-03-03
HRP20192099T1 (hr) 2020-03-06
AU2019210655A1 (en) 2019-08-22
KR20170138565A (ko) 2017-12-15
CY1122569T1 (el) 2021-01-27
US10287346B2 (en) 2019-05-14
HUE047146T2 (hu) 2020-04-28
PH12017501941A1 (en) 2018-03-19
EP3290441A4 (en) 2018-10-17
PL3290441T3 (pl) 2020-05-18
RU2017135353A3 (es) 2019-04-08
TW202328205A (zh) 2023-07-16
JP2023025285A (ja) 2023-02-21
LT3290441T (lt) 2020-02-10
TW202138389A (zh) 2021-10-16
ZA201907773B (en) 2021-05-26
DOP2017000248A (es) 2018-01-31
SG11201708848TA (en) 2017-11-29
MX2017013894A (es) 2018-03-01
CN107531791A (zh) 2018-01-02
KR102613528B1 (ko) 2023-12-12
ZA201708047B (en) 2020-01-29
JP6497760B2 (ja) 2019-04-10
PT3290441T (pt) 2019-12-02
EP3584260A1 (en) 2019-12-25
AU2016253886A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
CL2017002729A1 (es) Proteína de unión a rgma y su uso
BR112017003582A2 (pt) anticorpos, composições e usos
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CR20200290A (es) PÉPTIDOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DAÑO ARTICULAR (Divisional 2015-0466)
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
BR112018007017A2 (pt) polipeptídeos
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
UY35462A (es) Formulación de un polipéptido del factor viii.
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
MY194175A (en) Variant rnai
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
PE20171142A1 (es) Vectores para expresion de antigenos asociados a prostata
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
MX2015011860A (es) Materiales y metodos para mejorar la funcion pulmonar y para la prevencion y/o tratamiento de complicaciones pulmonares inducidas por radiacion.
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
BR112014027239A2 (pt) peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2017006748A (es) Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.